NovoCure

Valuation Analysis

About the Company

NovoCure en bref

NovoCure (NVCR) is currently trading at 12,46 € with a market capitalization of 1,4 Md €. The 52-week range spans from 8,57 € to 16,51 €; the current price is 24.5% below the yearly high. Year-over-year revenue growth stands at +12.3%.

💰 Dividende

NovoCure currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

7 analystes évaluent NovoCure (NVCR) au consensus : Acheter. L'objectif de cours moyen est de 22,94 €, soit un potentiel de +84.07% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 14,84 € à 41,89 €.

NovoCure : la thèse d'investissement en détail

NovoCure (NVCR) operates in the Healthcare — specifically Medical Devices — and is headquartered in Switzerland. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 12.3% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 75.45%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Buy with an average price target implying roughly 84.07% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 10.7% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

À surveiller

• The analyst consensus price target implies 84.07% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (10.7%).

Trading Data

Related Stocks in the Same Sector

Where can I buy NovoCure?

Compare top-rated brokers — low fees, trusted providers, fully regulated.